Elevance Health Inc. released its financial results for the third quarter of 2024, reporting a significant miss in earnings per share $(EPS)$ expectations. The company reported an EPS shortfall of $1.33, or 13.7%, primarily due to increased medical costs within its Medicaid business. Consequently, Elevance has lowered its EPS guidance for the year 2024 from $37.20 to $33.00, representing an 11.3% reduction, as they anticipate these Medicaid issues to persist. Following the announcement, Elevance's stock price experienced a notable decrease, falling by $52.61 per share, or 10.6%, closing at $444.35 on October 17, 2024. Elevance, headquartered in Indianapolis, provides health insurance plans, including managing Medicaid benefits for state-contracted beneficiaries. The company previously indicated expectations of increased Medicaid utilization for the second half of 2024, which had already impacted its stock price earlier in the year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.